

# ForPatients

by Roche

Duchenne Muscular Dystrophy (DMD)

## A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

**Trial Status**  
Recruiting

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT06128564 2022-000691-19  
BN43881

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT06128564 2022-000691-19 BN43881**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
Male

**Age**  
<= 3 Years

**Healthy Volunteers**  
No

---